Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Relapsed/Refractory Hematologic Malignancies
NCT00003885Phase 2Unknown
- Sponsor
- Our Lady of Mercy Medical Center
- Start
- Nov 1997
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), lymphoma, sponsored by Our Lady of Mercy Medical Center. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NCT00003885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003885.